Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:DRNA
- CUSIP: N/A
- Web: www.dicerna.com
Capitalization:- Market Cap: $57.32 million
- Outstanding Shares: 20,844,000
Average Prices:- 50 Day Moving Avg: $3.45
- 200 Day Moving Avg: $3.13
- 52 Week Range: $2.42 - $6.10
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.00
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $680,000.00
- Price / Sales: 84.30
- Book Value: $0.64 per share
- Price / Book: 4.30
Profitability:- EBIDTA: ($57,170,000.00)
- Net Margins: -8,474.12%
- Return on Equity: -168.65%
- Return on Assets: -92.82%
Debt:- Current Ratio: 9.57%
- Quick Ratio: 9.57%
Misc:- Average Volume: 108,430 shs.
- Beta: 2.35
- Short Ratio: 3.05
Frequently Asked Questions for Dicerna Pharmaceuticals (NASDAQ:DRNA)
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($1.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.54. The business earned $0.25 million during the quarter, compared to analysts' expectations of $0.08 million. Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. Dicerna Pharmaceuticals's revenue for the quarter was up 2400.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) EPS. View Dicerna Pharmaceuticals' Earnings History.
When will Dicerna Pharmaceuticals make its next earnings announcement?
Where is Dicerna Pharmaceuticals' stock going? Where will Dicerna Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued 1 year price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $4.00 to $13.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $7.25 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.
What are analysts saying about Dicerna Pharmaceuticals stock?
Here are some recent quotes from research analysts about Dicerna Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (8/22/2017)
- 2. Cowen and Company analysts commented, "DRNA reported 1Q17 results today." (5/9/2017)
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include ProQR Therapeutics N.V. (PRQR), Cidara Therapeutics (CDTX), Verona Pharma Plc (VRP), Adverum Biotechnologies (ADVM), MaxCyte (MXCT), Ophthotech Corporation (OPHT), Zafgen (ZFGN), Agile Therapeutics (AGRX), MEI Pharma (MEIP), Galmed Pharmaceuticals (GLMD), Intec Pharma (NTEC), Affimed N.V. (AFMD), Lipocine (LPCN), Applied Genetic Technologies Corporation (AGTC), Gemphire Therapeutics (GEMP), Pfenex (PFNX), Synthetic Biologics (SYN) and ProNAi Therapeutics (SRRA).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- David M. Madden Ph.D., Independent Chairman of the Board
- Douglas M. Fambrough Ph.D., President, Chief Executive Officer, Director
- John B. Green, Chief Financial Officer, Principal Financial Officer
- Bob D. Brown Ph.D., Senior Vice President, Chief Scientific Officer
- Theodore T. Ashburn M.D., Ph.D., Senior Vice President - Product Strategy & Operations
- Pankaj Bhargava M.D., Chief Medical Officer
- Ralf H. Rosskamp M.D., Chief Medical Officer
- James B. Weissman, Chief Business Officer
- Martin I Freed M.D., Independent Director
- Brian K. Halak Ph.D., Independent Director
Who owns Dicerna Pharmaceuticals stock?
Dicerna Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (11.65%), FMR LLC (11.30%), EcoR1 Capital LLC (3.68%), Palo Alto Investors LLC (2.40%), Vanguard Group Inc. (1.64%) and Omega Fund Management LLC (1.07%). Company insiders that own Dicerna Pharmaceuticals stock include Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.
Who sold Dicerna Pharmaceuticals stock? Who is selling Dicerna Pharmaceuticals stock?
Who bought Dicerna Pharmaceuticals stock? Who is buying Dicerna Pharmaceuticals stock?
Dicerna Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Bourgeon Capital Management LLC, Palo Alto Investors LLC, Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Douglas Fambrough and James B Weissman. View Insider Buying and Selling for Dicerna Pharmaceuticals.
How do I buy Dicerna Pharmaceuticals stock?
Shares of Dicerna Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of Dicerna Pharmaceuticals stock can currently be purchased for approximately $2.75.
MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $7.25 (163.64% upside) |
Analysts' Ratings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/14/2017 | Chardan Capital | Reiterated Rating | Hold | | Medium |  |
| 5/23/2017 | HC Wainwright | Reiterated Rating | Buy -> Buy | $5.00 | Medium | |
| 5/9/2017 | Cowen and Company | Reiterated Rating | Buy | | High | |
| 4/2/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $8.00 -> $7.00 | Low | |
| 2/1/2017 | Leerink Swann | Reiterated Rating | Mkt Perform | | N/A | |
| 9/28/2016 | Stifel Nicolaus | Reiterated Rating | Buy | $13.00 | N/A | |
(Data available from 8/23/2015 forward)
Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)Earnings History by Quarter for Dicerna Pharmaceuticals (NASDAQ DRNA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.70) | | | | | N/A | |
| 8/10/2017 | Q2 2017 | ($0.61) | ($1.15) | $0.08 million | $0.25 million | View | N/A | |
| 5/8/2017 | Q1 2017 | ($0.65) | ($0.68) | $0.08 million | $0.13 million | View | Listen | |
| 3/30/2017 | Q4 2016 | ($0.73) | ($0.68) | | $0.13 million | View | N/A | |
| 11/7/2016 | Q316 | ($0.87) | ($0.68) | | $162.00 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.84) | ($0.75) | | | View | N/A | |
| 5/9/2016 | Q116 | ($0.86) | ($0.76) | | | View | N/A | |
| 3/10/2016 | Q415 | ($0.84) | ($0.76) | $2.50 million | | View | Listen | |
| 11/10/2015 | Q315 | ($0.84) | ($0.82) | | | View | Listen | |
| 8/6/2015 | Q215 | ($0.78) | ($0.86) | | $0.18 million | View | N/A | |
| 5/11/2015 | Q1 | ($0.73) | ($0.79) | $600.00 million | | View | Listen | |
| 3/12/2015 | Q414 | ($0.57) | ($0.63) | $1.45 million | | View | N/A | |
| 11/6/2014 | Q3 2014 | ($0.63) | ($0.63) | | | View | N/A | |
| 8/7/2014 | Q2 2014 | ($0.42) | ($0.64) | | | View | N/A | |
| 5/13/2014 | Q114 | ($0.52) | ($0.76) | | | View | N/A | |
| 3/27/2014 | | ($0.62) | ($0.20) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)2017 EPS Consensus Estimate: ($2.53)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.73) | ($0.59) | ($0.66) |
| Q2 2017 | 2 | ($0.73) | ($0.68) | ($0.71) |
| Q3 2017 | 2 | ($0.67) | ($0.50) | ($0.59) |
| Q4 2017 | 2 | ($0.66) | ($0.50) | ($0.58) |
(Data provided by Zacks Investment Research)
Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Dicerna Pharmaceuticals (NASDAQ:DRNA)Insider Ownership Percentage: 29.41%
Institutional Ownership Percentage: 56.05%
Insider Trades by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/16/2016 | Dennis Langer | Director | Sell | 23,766 | $3.52 | $83,656.32 | |
| 11/15/2016 | Douglas Fambrough | CEO | Buy | 33,100 | $3.71 | $122,801.00 | |
| 5/12/2016 | James B Weissman | Insider | Buy | 5,000 | $3.29 | $16,450.00 | |
| 11/25/2014 | James E Flynn | Insider | Sell | 321,965 | $11.36 | $3,657,522.40 | |
| 11/7/2014 | James E Flynn | Insider | Sell | 214,164 | $9.05 | $1,938,184.20 | |
| 10/15/2014 | James E Flynn | Insider | Sell | 117,778 | $10.86 | $1,279,069.08 | |
| 10/14/2014 | James E Flynn | Major Shareholder | Sell | 36,115 | $11.02 | $397,987.30 | |
| 10/10/2014 | James E Flynn | Major Shareholder | Sell | 30,214 | $12.13 | $366,495.82 | |
| 2/4/2014 | James E Flynn | Insider | Buy | 1,000,000 | $15.00 | $15,000,000.00 | |
| 2/4/2014 | Stephen J Hoffman | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Latest Headlines for Dicerna Pharmaceuticals (NASDAQ:DRNA)
| Source: |
|
| Date | Headline |
|---|
 | Dicerna Pharmaceuticals, Inc. (DRNA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 22 at 9:26 PM |
| Dicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM |
| Dicerna Pharmaceuticals, Inc. (DRNA) Given "Hold" Rating at Chardan Capital
www.americanbankingnews.com - August 14 at 8:36 AM |
 | Edited Transcript of DRNA earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 11 at 5:23 AM |
| Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Releases Earnings Results, Misses Expectations By $0.47 EPS
www.americanbankingnews.com - August 10 at 10:42 PM |
| Dicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - August 10 at 7:16 PM |
| Dicerna Pharmaceuticals posts 2Q loss
finance.yahoo.com - August 10 at 7:16 PM |
| Dicerna to Report Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
finance.yahoo.com - August 3 at 5:06 PM |
| Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 24 at 8:28 PM |
| Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - July 22 at 9:04 AM |
| Dicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 6:51 PM |
| Zacks Investment Research Downgrades Dicerna Pharmaceuticals, Inc. (DRNA) to Sell
www.americanbankingnews.com - July 18 at 10:20 PM |
| Dicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC
finance.yahoo.com - July 17 at 11:28 AM |
| Dicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 26 at 6:49 PM |
 | Dicerna Pharmaceuticals (DRNA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 5:44 PM |
| Dicerna to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 5:29 PM |
 | 7 Speculative Biotech and Pharma Stocks That Could Still Double (or More)
247wallst.com - May 31 at 9:41 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 30 at 4:48 PM |
 | Bain Capital raises $720 million for life sciences fund
www.reuters.com - May 23 at 12:24 PM |
| Bain Capital rakes in $720M for first life sciences fund
finance.yahoo.com - May 23 at 12:24 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - May 23 at 7:36 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 16 at 8:18 PM |
| Dicerna Pharmaceuticals Inc (DRNA) to Post Q2 2017 Earnings of ($0.68) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 11 at 8:52 AM |
| Cowen and Company Reiterates Buy Rating for Dicerna Pharmaceuticals Inc (DRNA)
www.americanbankingnews.com - May 9 at 10:28 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Announces Earnings Results
www.americanbankingnews.com - May 9 at 1:56 PM |
| Dicerna Pharmaceuticals posts 1Q loss
finance.yahoo.com - May 9 at 6:44 AM |
| Edited Transcript of DRNA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 6:44 AM |
| Investor Network: Dicerna Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 4:41 PM |
| Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update
finance.yahoo.com - May 8 at 4:41 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 5 at 10:52 AM |
| Dicerna Pharmaceuticals (DRNA) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 6:32 PM |
| Dicerna Pharmaceuticals (DRNA) Earning Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 6:04 PM |
| Dicerna to Report First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
finance.yahoo.com - May 1 at 4:39 PM |
| Somewhat Positive News Coverage Unlikely to Affect Dicerna Pharmaceuticals (DRNA) Share Price
www.americanbankingnews.com - April 28 at 5:45 PM |
| Dicerna Pharmaceuticals (DRNA) Receiving Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 25 at 6:00 PM |
| Dicerna Pharmaceuticals (DRNA) Earning Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 20 at 10:09 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 17 at 7:52 PM |
| Somewhat Favorable Media Coverage Somewhat Likely to Effect Dicerna Pharmaceuticals (DRNA) Stock Price
www.americanbankingnews.com - April 16 at 1:50 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Price Target Lowered to $5.00 at HC Wainwright
www.americanbankingnews.com - April 14 at 7:12 AM |
| Somewhat Favorable News Coverage Somewhat Likely to Effect Dicerna Pharmaceuticals (DRNA) Share Price
www.americanbankingnews.com - April 13 at 6:15 PM |
| Dicerna Announces Closing of $70 Million Convertible Preferred Stock Financing
finance.yahoo.com - April 12 at 9:35 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 11 at 10:18 PM |
| Dicerna Pharmaceuticals (DRNA) Presents At The 24th Annual Future Leaders in the Biotech Industry Conference - Slideshow
seekingalpha.com - April 11 at 12:48 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 10 at 11:51 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Price Target Cut to $5.00 by Analysts at HC Wainwright
www.americanbankingnews.com - April 10 at 8:47 AM |
| Jefferies Group LLC Reiterates "Buy" Rating for Dicerna Pharmaceuticals Inc (DRNA)
www.americanbankingnews.com - April 9 at 10:32 AM |
| Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: 2016 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 9:27 AM |
| ETFs with exposure to Dicerna Pharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:27 AM |
| Jefferies Group Weighs in on Dicerna Pharmaceuticals Inc's FY2021 Earnings (DRNA)
www.americanbankingnews.com - April 3 at 1:02 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 2 at 10:31 PM |
Dicerna Pharmaceuticals (DRNA) Chart for Wednesday, August, 23, 2017
